SolidSMART : AI Driven Solid State Development
SolidSMART: Formulation & Screening Software
Accelerate Drug Development with Advanced Screening and Prediction.
SolidSMART is a groundbreaking drug development software designed to revolutionize pharmaceutical research. With its precision-driven algorithms, SolidSMART accelerates API development and screening processes, delivering actionable insights for pH solubility, salt selection, polymorph prediction, ASD polymer screening in record time.
Empowering both New Chemical Entities (NCE) and generic pharmaceutical companies, SolidSMART simplifies complex workflows, reducing costs, saving time, and boosting confidence in your results. Say goodbye to traditional trial-and-error methods and embrace the future of pharmaceutical innovation with SolidSMART: Speed, Precision, and Simplicity in Every Step.
- pH Solubility Prediction
- Insilco Salt Screening for Enhanced Drug Development
- Comprehensive Solvent Selection for Polymorph Formation
- ASD Polymer Screening
pH Solubility Prediction
Advanced pH Solubility Prediction for Streamlined Formulation Development
SolidSMART offers precise pH solubility predictions across a broad pH range (1.2 to 9) in under an hour. Covering 10 key dissolution media, including gastric and intestinal fluids, with 85% accuracy, it delivers actionable insights at 10°C, 25°C, and 50°C. This advanced solution accelerates formulation development while ensuring alignment with real-world conditions.
- Slow Process: Traditional pH solubility testing takes up to 14 days, delaying projects by 30%.
- Limited Scope: Testing in just 3–5 media misses 70% of real-world conditions.
- Temperature Gaps: Ignoring climate effects causes 20% solubility variations.
- Rapid Predictions: Solubility data from pH 1.2 to 9 in less than an hour.
- Wide Media Coverage: Comprehensive testing across 10 dissolution media types, including gastric and intestinal fluids.
- Accurate Buffer Simulations: 85% accuracy across various buffer solutions.
- Temperature Flexibility: Solubility assessments at 10°C, 25°C, and 50°C to accommodate different climatic conditions.
- For NCEs: Accurate solubility predictions enable stable and effective drug formulations early on, avoiding costly reformulations.
- For Generic Drug Companies: Streamlined bioequivalence studies ensure consistency with branded counterparts.
Insilco Salt Screening for Enhanced Drug Development
Screen 56 Salt Forms in Just One Hour!
Accelerate your salt screening process with SolidSMART. The software screens Active Pharmaceutical Ingredients (APIs) against 56 salt forms, predicting compatibility and stability across multiple temperatures (10°C, 25°C, 50°C) within one hour. This results in significant time and cost savings while improving your ability to select optimal salt forms for enhanced solubility and stability.
Traditional approaches to salt selection and screening present multiple roadblocks:
- Up to 6 months required for conventional salt screening.
- Limited screening scope overlooks potential salt candidates.
- Gut absorption of salts remains unpredictable
- Missed salt forms result in lost IP advantages.
- Screening all possible salts experimentally is impractical and costly.
- Rapid Screening : Screen APIs against FDA approved 56 salt forms within an hour.
- Stability Predictions : Evaluate stability at 10°C, 25°C, and 50°C.
- Gut Solubility : 80% accuracy in predicting newly formed salt solubility in water and gut environments.
- Cost Efficiency : Minimize expenses associated with extended screening and manual testing.
For NCEs and Generic Formulations: Quick and precise salt screening supports better salt selection, enhancing drug stability and performance. This facilitates faster market entry and ensures regulatory compliance.
Polymorph screening
Automated XRD Analysis for Unparalleled Accuracy
SolidSMART predicts the formation of new polymorphs based on molecular structures, screening APIs against 11,000 solvent systems at temperatures ranging from 10°C to 50°C. With 80% accuracy, the software helps researchers identify optimal solvents for crystallization, reducing manual labor and experimentation time.
- Poor solvent choices delay screening by up to 70%.
- 50% of polymorphs remain undetected due to limited solvent space exploration.
- High failure rates lead to costly rework and analysis.
- Reproduction of Polymorphs
Automated File Processing: Analyze hundreds of XRD files in less than 5 minutes.
High Precision: Accurately detects novel or non-infringing forms, eliminating human errors.
Time Efficiency: Significantly reduces the effort and time required to process large datasets.
Reduced Dependency: Minimizes reliance on manual analysis and IP personnel for data interpretation.
- For NCE Developers: Enhance stability, avoid patent conflicts, and streamline their development cycle.
- For Generic Pharmaceutical Firms: Benefit from consistent batch production and reduced risk of variability, ensuring regulatory compliance.
ASD Polymer Screening
SolidSMART enables rapid and precise screening of API-polymer interactions, predicting miscibility, stability, and solubility in key pharmaceutical environments. By assessing 34 polymers at various temperatures and weight fractions, it ensures optimized selection for amorphous solid dispersions (ASDs), reducing phase separation risks and enhancing bioavailability.
Industry Challenges
Choosing a right polymer is very difficult and time consuming
- Traditional methods assess only a few polymers, missing optimal candidates.
- Incorrect API-to-polymer ratios cause 70% of phase separation cases, leading to formulation failures.
- Phase separation risks increase development timelines and reformulation costs
SolidSMART Key Features
- Evaluate 34 polymers for API compatibility across multiple temperatures
- Assess API-polymer compatibility at different weight fractions
- Predict the stability of API-polymer complexes for long-term formulation success
- Determine API-polymer complex solubility in water and gut environments for enhanced bioavailability.
Applications
- For NCEs: Improve early-stage formulation design by selecting the most compatible polymer, ensuring stable ASDs.
- For Generic Drug Manufacturers: Optimize bioequivalence and stability, preventing unexpected dissolution failures